Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced...

                   
yahoo.com     Jul 23, 2008            

Wednesday July 23, 12:05 am ET -- Wellcome Trust and Aeras Global TB Vaccine Foundation have agreed to provide GBP 8 million in funding for Phase IIb clinical trial that is expected to commence in 2009-- The vaccine candidate, MVA85A, has been granted orphan drug designation by the European Medicines Agency (EMEA) -- If successful, MVA85A would be the first new vaccine licensed to prevent tuberculosis in over 80 years OXFORD, England & ROCKVILLE, Md.--(BUSINESS WIRE)--The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS - News ) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the “Consortium”), to further develop MVA85A, the world’s most clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its... [read full story]                    

FULL COVERAGE
                   

Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced...

genengnews.com     Jul 23, 2008          

News source: Business Wire The University of Oxford and Emergent BioSolutions Inc. announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further develop...                    

comments

                   

Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced...

redorbit.com     Jul 23, 2008          

Posted on: Wednesday, 23 July 2008, 00:00 CDT The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the...                    

comments

Emergent BioSolutions and University of Oxford Join Hands to Develop TB Vaccine

redorbit.com     Jul 23, 2008          

The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis.                    

comments

Emergent BioSolutions and University of Oxford join hands to develop TB vaccine

pharmaceutical-business-review.com     Jul 24, 2008          

The University of Oxford and Emergent BioSolutions have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium, to further develop MVA85A, a clinically advanced vaccine candidate for the prevention of tuberculosis.                    

comments

Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's...

genengnews.com     Jul 24, 2008          

News source: Business Wire Emergent BioSolutions Inc. announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases (NIAID) to fund the continued...                    

comments

                   

Emergent BioSolutions Awarded Two Grants from NIAID to Support Development of the Company's...

yahoo.com     Jul 24, 2008          

ROCKVILLE, Md.----Emergent BioSolutions Inc. announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases to fund the continued development of the...                    

comments

Emergent BioSolutions Awarded Two Grants From NIAID to Support Development of the Company's...

redorbit.com     Jul 24, 2008          

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases (NIAID) to fund the continued development of the...                    

comments

                   

Emergent Biosolutions And University Of Oxford Form Joint Venture To Develop An Advanced...

medicalnewstoday.com     Jul 24, 2008          

The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) has announced that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further develop MVA85A, the world's...                    

comments

Emergent Wins Two NIAID Grants for Vaccine Development Program

redorbit.com     Jul 24, 2008          

Emergent BioSolutions has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases to fund the continued development of the company's recombinant botulinum vaccine and...                    

comments

Emergent, Oxford form joint venture

lsj.com     Jul 25, 2008          

Evening update Jeremy W. Steele • jwsteele@lsj.com • July 24, 2008 • From LSJ.com ROCKVILLE, Md. - Emergent BioSolutions Inc. has formed a joint venture with the University of Oxford to develop a tuberculosis vaccine. The...                    

comments

1 2 next